- Nivolumab in treatment of NSCLC2016 | Publication without faculty affiliation
- Nivolumab in the treatment of head and neck cancer2017 | Faculty of Medicine in Hradec Králové
- Nivolumab in the treatment of squamous cell carcinoma of esophagus2021 | Faculty of Medicine in Hradec Králové
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Nivolumab-Induced Psoriasis in a Patient with Lung Cancer. Case Report2022 | Faculty of Medicine in Hradec Králové
- Nivolumab-induced hepatitis in a patient treated for malignant melanoma2020 | Faculty of Medicine in Pilsen
- Immunotherapy in squamous NSCLC - nivolumab clinical data, our experiences with nivolumab treatment2018 | Faculty of Medicine in Pilsen
- Combination of nivolumab and relatlimab – a new option in the treatment of malignant melanoma2023 | Faculty of Medicine in Hradec Králové
- Complete remission of metastatic malignant melanoma treated with nivolumab, complicated with pulmonary toxicity2018 | Faculty of Medicine in Hradec Králové
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation2019 | Publication without faculty affiliation
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Clinical dilemma of lung cancer treatment with anti-PD-1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling - case report2020 | First Faculty of Medicine
- Patient with generalized melanoma treated with nivolumab with long-term response after previous failure of combined chemotherapy2019 | First Faculty of Medicine
- Nivolumab in a patient with NSCLC: a protracted but effective treatment full of toxicities - case report2023 | Third Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CA209-067Publication without faculty affiliation
- Možnosti využití nivolumabu v imunoterapii melanomu2022 | First Faculty of Medicine
- Výzkumná zpráva Fakultní nemocnice ke klinickému Hodnocení CA209-067Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-238Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-214Publication without faculty affiliation
- Nemalobuněčný karcinom plic - vzácný nežádoucí účinek léčby nivolumabem2022 | First Faculty of Medicine
- Rapid response to mFOLFOX6 + nivolumab combination therapy in a patient with generalized gastric adenocarcinoma2023 | Third Faculty of Medicine
- Hepatic Injury Induced by a Single Dose of Nivolumab - a Case Report and Literature Review2019 | Faculty of Medicine in Hradec Králové
- Komentář k článku: Nivolumab v léčbě Hodgkinova lymfomu2017 | First Faculty of Medicine
- Recent advances in tartgeted therapy of renal cell carcinoma2016 | First Faculty of Medicine
- Adjuvant therapy for melanoma in real world2023 | Faculty of Medicine in Hradec Králové
- Failure of adjuvant treatment for malignant melanoma - what next?2021 | Publication without faculty affiliation
- Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study2023 | First Faculty of Medicine
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Central Library of Charles University, Third Faculty of Medicine
- Immunotherapy of renal cell carcinoma2018 | First Faculty of Medicine